<qa>  What is the primary endpoint of the trial?This is an open-label phase II trial with weekly gemcitabine plus high-dose 5-FUleucovorin infusion HDFL for patients with advanced or metastatic carcinoma of the biliary tract. The primary endpoint is patients response and the secondary endpoints are chemotherapy-related toxicity, time to disease progression and overall survival. . 